Reassessing the safety signal: Dihydropyridine calcium channel blockers in the era of quadruple therapy for heart failure. Author's reply

We read with interest the letter by Wang et al [1] regarding our recently published paper on prescription patterns and outcomes associated with dihydropyridine calcium channel blockers (DHP-CCBs) across the spectrum of chronic heart failure (HF) [2].